Volume 94, Issue 2
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



The health-care needs and resources of disease-endemic regions such as west Africa have been a major focus during the recent Ebola outbreak. On the basis of that experience, we call attention to two priorities that have unfortunately been ignored thus far: 1) the development of clinical research facilities and 2) the training of host country investigators to ensure that the facilities and expertise necessary to evaluate candidate interventions are available on-site in endemic regions when and where they are needed. In their absence, as illustrated by the recent uncertainty about the use of antivirals and other interventions for Ebola virus disease, the only treatment available may be supportive care, case fatality rates may be unacceptably high and there may be long delays between the time potential interventions become available and it becomes clear whether those interventions are safe or effective. On the basis of our experience in Mali, we urge that the development of clinical research facilities and the training of host country investigators be prioritized in disease-endemic regions such as west Africa.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...



  1. Gatherer D, , 2014. The 2014 Ebola virus disease outbreak in West Africa. J Gen Virol 95: 16191624.[Crossref] [Google Scholar]
  2. Anonymous, 2014. Barriers to trust: an outbreak of Ebola highlights the difficulties of implementing public health measures. Nature 511: 126. [Google Scholar]
  3. Brady O, , 2014. Scale up the supply of experimental drugs: estimates of the probable impact of the outbreak show that existing stocks of potentially useful medicines are insufficient. Nature 512: 233.[Crossref] [Google Scholar]
  4. Pronker ES, Weenen TC, Commandeur HR, Osterhaus ADME, Classen HJHM, , 2011. The gold industry standard for risk and cost of drug and vaccine development revisited. Vaccine 29: 58465849.[Crossref] [Google Scholar]
  5. Morgan S, Grootendorst P, Lexchin J, Cunningham C, Greyson D, , 2011. The cost of drug development: a systematic review. Health Policy 100: 417.[Crossref] [Google Scholar]
  6. Reardon S, , 2014. Ebola treatments caught in limbo. Nature 511: 520.[Crossref] [Google Scholar]
  7. Anonymous, 1996. Guidance for Industry, E6 Good Clinical Practice: Consolidated Guidance. Available at: http://www.fda.gov/downloads/Drugs/…/Guidances/ucm073122.pdf. Accessed September 21, 2015. [Google Scholar]
  8. Anonymous, 2005. International Conference on Harmonisation (ICH) Guideline for Good Clinical Practice. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed November 2, 2015. [Google Scholar]
  9. WHO, 2005. Health Expenditure Per Capita, by Country, 1995–2013. Available at: http://apps.who.int/gho/data/node.main.HEALTHEXPCAPBYCOUNTRY?lang=en. Accessed September 21, 2015. [Google Scholar]
  10. De D, Krogstad FM, Cogswell FB, Krogstad DJ, , 1996. Aminoquinolines that circumvent chloroquine resistance in Plasmodium falciparum in vitro. Am J Trop Med Hyg 55: 579583. [Google Scholar]
  11. Mzayek F, Haiyan D, Mather FJ, Wasilevich EC, Liu H, Hadi CM, Chansolme DH, Murphy HA, Melek BH, Tenaglia AN, Mushatt DM, Dreisbach AW, Lertora JJL, Krogstad DJ, , 2007. Randomized, dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials 2: e6.[Crossref] [Google Scholar]
  12. Touré YT, , 1989. The current state of studies of malaria vectors and the antivectorial campaign in West Africa. Trans R Soc Trop Med Hyg 83 (Suppl): 3941.[Crossref] [Google Scholar]
  13. Gwadz RW, , 1994. Genetic approaches to malaria control: how long the road? Am J Trop Med Hyg 50 (Suppl): 116125. [Google Scholar]
  14. Krogstad DJ, , 2015. Studies of a Candidate Aminoquinoline Antimalarial (AQ-13). NCT 01614964. Available at: https://clinicaltrials.gov/ct2/show/NCT01614964?term=NCT+01614964&rank=1. Accessed September 21, 2015. [Google Scholar]
  15. Koita OA, Janka JJ, Traoré B, Josepha MT, Mzayek F, Sachdev V, Wang X, Sanogo K, Sangaré L, Mendelsohn L, Kato GJ, Masur H, Gladwin MT, Krogstad DJ, , 2010. Intravascular hemolysis, nitric oxide consumption and pulmonary hypertension in children with severe malarial anemia. J Infect Dis 202: 791800.[Crossref] [Google Scholar]
  16. Anonymous, 2014. Ebola: a failure of international collective action. Lancet 384: 637.[Crossref] [Google Scholar]
  17. Bausch DG, Towner JS, Dowell SF, Kaducu F, Lukwiya M, Sanchez A, Nichol ST, Ksiazek TG, Rollin PE, , 2007. Assessment of the risk of Ebola virus transmission from bodily fluids and fomites. J Infect Dis 196 (Suppl 2): S142S147.[Crossref] [Google Scholar]
  18. Leroy EM, Baize S, Lu CY, McCormick JB, Georges AJ, Georges-Courbot MS, Lansoud-Soukate J, Fisher-Hoch SP, , 2000. Diagnosis of Ebola haemorrrhagic fever by RT-PCR in an epidemic setting. J Med Virol 60: 463467.[Crossref] [Google Scholar]
  19. Towner JS, Rollin PE, Bausch DG, Sanchez A, Crary SM, Vincent M, Lee WF, Spriopoulou CF, Ksiazek TG, Lukwiya M, Kaducu F, Downing R, Nichol ST, , 2004. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol 78: 43304331.[Crossref] [Google Scholar]
  20. Drosten C, Göttig S, Schilling S, Asper M, Panning M, Schmitz H, Günther S, , 2002. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 40: 23232330.[Crossref] [Google Scholar]
  21. Green A, , 2014. WHO and partners launch Ebola response plan. Lancet 384: 481.[Crossref] [Google Scholar]
  22. Martin JE, Sullivan NJ, Enama ME, Gordon IJ, Roederer M, Koup RA, Bailer RT, Chakrabarti BK, Bailey MA, Gomes PL, Andrews CA, Moodie Z, Gu L, Stein JA, Nabel GJ, Graham BS, the VRD 204 Study Team, , 2006. A DNA vaccine for Ebola virus is safe and immunogenic in a phase I clinical trial. Clin Vaccine Immunol 13: 12671277.[Crossref] [Google Scholar]
  23. Feldmann H, Jones SM, Daddario-DiCaprio KM, Geisbert JB, Ströher U, Grolla A, Bray M, Fritz EA, Fernando L, Feldmann F, Hensley LE, Geisbert TW, , 2007. Effective post-exposure treatment of Ebola infection. PLoS One 3: e2. [Google Scholar]
  24. Henao-Restrepo AM, Longini IM, Egger M, Dean NE, Edmunds WJ, Camacho A, Miles W, Carroll MW, Doumbia M, Draquez B, Duraffour S, Enwere G, Grais R, Gunther S, Hossmann S, Kondé MK, Kone S, Kuisma E, Levine MM, Mandal S, Norheim G, Riveros X, Soumah A, Trelle S, Vicari AS, Watson CH, Keita S, Kieny MP, Rǿttingen J-A, , 2015. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386: 857866.[Crossref] [Google Scholar]

Data & Media loading...

Supplementary PDF

  • Received : 16 May 2015
  • Accepted : 25 Sep 2015
  • Published online : 03 Feb 2016

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error